Allergy Sales That Rose Up Your Nose

The Allergy Market in 2014
The Allergy Market in 2014

In 2014, two intranasal steroids for the treatment of allergic rhinitis received FDA approval for Rx-to-OTC switch—Sanofi’s Nasacort Allergy 24 Hour and GlaxoSmithKline’s Flonase Allergy Relief. Nasacort entered the OTC market in February 2014 and according to recently released data from Kline’s Nonprescription Drugs USA study, from February through December 2014, the product generated about $100 million in sales at the manufacturers’ level. Kline pegs the overall allergy market up 10.0% to over $1.8 billion in sales at the manufacturers’ level.Read More »